FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296306321> ?p ?o ?g. }

• W4296306321 abstract "Crohn’s disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) with the involvement of immune cells and molecules, including cytokines, chemokines and proteases. A previous extensive review about the molecular biology of matrix metalloproteases (MMPs) and tissue inhibitors of metalloproteases (TIMPs), related to intestinal barrier destruction and restoration functions in IBD, is here complemented with the literature from the last five years. We also compare IBD as a prototypic mucosal inflammation of an epithelial barrier against microorganisms with inflammatory retinopathy as a disease with a barrier dysfunction at the level of blood vessels. Multiple reasons are at the basis of halting clinical trials with monoclonal antibodies against MMP-9 for IBD treatment. These include (i) the absence of a causative role of MMP-9 in the pathology in animal models of IBD, (ii) the fact that endotoxins, crossing the intestinal barrier, induce massive local release of both neutrophil collagenase (MMP-8) and gelatinase B (MMP-9), (iii) insufficient recognition that MMPs modify the activities of cytokines, chemokines and their receptors, (iv) ignorance that MMPs exist as mixtures of proteoforms with different posttranslational modifications and with different specific activities and (v) the fact that MMPs and TIMPs act in an interactive network, possibly having also beneficial effects on IBD evolution. Nevertheless, inhibition of MMPs may be a useful therapeutic approach during specific IBD disease phases or in specific sub-phenotypes. This temporary “window of opportunity” for MMP-9 inhibition may be complemented by a locoregional one, provided that the pharmacological agents are targeted in time to affected tissues, as is achieved in ophthalmological inflammation. Thus, in order to discover spatial and temporal windows of opportunity for MMP inhibition as treatment of IBD, more preclinical work including well controlled animal studies will be further needed. In this respect, MMP-9/NGAL complex analysis in various body compartments is helpful for better stratification of IBD patients who may benefit from anti-MMP-9." @default.
• W4296306321 created "2022-09-19" @default.
• W4296306321 creator A5019474609 @default.
• W4296306321 creator A5048493199 @default.
• W4296306321 creator A5073509553 @default.
• W4296306321 date "2022-09-09" @default.
• W4296306321 modified "2023-10-17" @default.
• W4296306321 title "How to place the duality of specific MMP-9 inhibition for treatment of inflammatory bowel diseases into clinical opportunities?" @default.
• W4296306321 cites W1428077152 @default.
• W4296306321 cites W1581404300 @default.
• W4296306321 cites W1910028331 @default.
• W4296306321 cites W1944754896 @default.
• W4296306321 cites W1970915918 @default.
• W4296306321 cites W1978591675 @default.
• W4296306321 cites W1982304490 @default.
• W4296306321 cites W1984483611 @default.
• W4296306321 cites W1985705655 @default.
• W4296306321 cites W1998986941 @default.
• W4296306321 cites W2008038069 @default.
• W4296306321 cites W2016673597 @default.
• W4296306321 cites W2016859011 @default.
• W4296306321 cites W2019492870 @default.
• W4296306321 cites W2024346860 @default.
• W4296306321 cites W2036662231 @default.
• W4296306321 cites W2056078450 @default.
• W4296306321 cites W2066944027 @default.
• W4296306321 cites W2102084025 @default.
• W4296306321 cites W2111533130 @default.
• W4296306321 cites W2128835447 @default.
• W4296306321 cites W2135423586 @default.
• W4296306321 cites W2143625465 @default.
• W4296306321 cites W2154660523 @default.
• W4296306321 cites W2173095346 @default.
• W4296306321 cites W2225696827 @default.
• W4296306321 cites W2323788043 @default.
• W4296306321 cites W2466188566 @default.
• W4296306321 cites W2507575989 @default.
• W4296306321 cites W2597953137 @default.
• W4296306321 cites W2604970475 @default.
• W4296306321 cites W2604988393 @default.
• W4296306321 cites W2617192664 @default.
• W4296306321 cites W2739397996 @default.
• W4296306321 cites W2753479285 @default.
• W4296306321 cites W2757080426 @default.
• W4296306321 cites W2773912782 @default.
• W4296306321 cites W2779922261 @default.
• W4296306321 cites W2780570824 @default.
• W4296306321 cites W2799617155 @default.
• W4296306321 cites W2803646659 @default.
• W4296306321 cites W2807769634 @default.
• W4296306321 cites W2884572336 @default.
• W4296306321 cites W2905511778 @default.
• W4296306321 cites W2910536907 @default.
• W4296306321 cites W2949502906 @default.
• W4296306321 cites W2954149465 @default.
• W4296306321 cites W2970887981 @default.
• W4296306321 cites W2979551472 @default.
• W4296306321 cites W2982061527 @default.
• W4296306321 cites W2982236095 @default.
• W4296306321 cites W2984945573 @default.
• W4296306321 cites W2988446362 @default.
• W4296306321 cites W2994828781 @default.
• W4296306321 cites W2998424148 @default.
• W4296306321 cites W3001475912 @default.
• W4296306321 cites W3016724352 @default.
• W4296306321 cites W3026698453 @default.
• W4296306321 cites W3095519721 @default.
• W4296306321 cites W3116925555 @default.
• W4296306321 cites W3133968906 @default.
• W4296306321 cites W3134123179 @default.
• W4296306321 cites W3144084593 @default.
• W4296306321 cites W3158439775 @default.
• W4296306321 cites W3160939858 @default.
• W4296306321 cites W3165031219 @default.
• W4296306321 cites W3197827253 @default.
• W4296306321 cites W3205942131 @default.
• W4296306321 cites W3217598357 @default.
• W4296306321 cites W4200210268 @default.
• W4296306321 cites W4220772416 @default.
• W4296306321 cites W4220983406 @default.
• W4296306321 cites W4226137497 @default.
• W4296306321 cites W4229445884 @default.
• W4296306321 cites W4280568001 @default.
• W4296306321 cites W4281675432 @default.
• W4296306321 cites W4283331795 @default.
• W4296306321 cites W4284990126 @default.
• W4296306321 doi "https://doi.org/10.3389/fimmu.2022.983964" @default.
• W4296306321 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36164340" @default.
• W4296306321 hasPublicationYear "2022" @default.
• W4296306321 type Work @default.
• W4296306321 citedByCount "6" @default.
• W4296306321 countsByYear W42963063212022 @default.
• W4296306321 countsByYear W42963063212023 @default.
• W4296306321 crossrefType "journal-article" @default.
• W4296306321 hasAuthorship W4296306321A5019474609 @default.
• W4296306321 hasAuthorship W4296306321A5048493199 @default.
• W4296306321 hasAuthorship W4296306321A5073509553 @default.
• W4296306321 hasBestOaLocation W42963063211 @default.
• W4296306321 hasConcept C109523444 @default.
• W4296306321 hasConcept C126322002 @default.

• next